These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

872 related items for PubMed ID: 19344980

  • 1. Treatments for psoriasis and the risk of malignancy.
    Patel RV, Clark LN, Lebwohl M, Weinberg JM.
    J Am Acad Dermatol; 2009 Jun; 60(6):1001-17. PubMed ID: 19344980
    [Abstract] [Full Text] [Related]

  • 2. From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies.
    Hugh J, Van Voorhees AS, Nijhawan RI, Bagel J, Lebwohl M, Blauvelt A, Hsu S, Weinberg JM.
    J Am Acad Dermatol; 2014 Jan; 70(1):168-77. PubMed ID: 24184141
    [Abstract] [Full Text] [Related]

  • 3. Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies.
    Naldi L.
    Clin Dermatol; 2010 Jan; 28(1):88-92. PubMed ID: 20082957
    [Abstract] [Full Text] [Related]

  • 4. Advancements in the treatment of psoriasis: role of biologic agents.
    Rich SJ, Bello-Quintero CE.
    J Manag Care Pharm; 2004 Jan; 10(4):318-25. PubMed ID: 15298530
    [Abstract] [Full Text] [Related]

  • 5. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks.
    Naldi L, Griffiths CE.
    Br J Dermatol; 2005 Apr; 152(4):597-615. PubMed ID: 15840088
    [Abstract] [Full Text] [Related]

  • 6. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
    Garber C, Creighton-Smith M, Sorensen EP, Dumont N, Gottlieb AB.
    J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
    [Abstract] [Full Text] [Related]

  • 7. Cutaneous malignancies during treatment with efalizumab and infliximab: When temporal relationship does not mean causality.
    Di Lernia V, Ricci C.
    J Dermatolog Treat; 2011 Aug; 22(4):229-32. PubMed ID: 20666674
    [Abstract] [Full Text] [Related]

  • 8. [Narrow-band UVB therapy in psoriasis vulgaris: good practice guideline and recommendations of the French Society of Photodermatology].
    Beani JC, Jeanmougin M.
    Ann Dermatol Venereol; 2010 Jan; 137(1):21-31. PubMed ID: 20110064
    [Abstract] [Full Text] [Related]

  • 9. The risk of melanoma and hematologic cancers in patients with psoriasis.
    Reddy SP, Martires K, Wu JJ.
    J Am Acad Dermatol; 2017 Apr; 76(4):639-647.e2. PubMed ID: 27876302
    [Abstract] [Full Text] [Related]

  • 10. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population.
    Asgari MM, Ray GT, Geier JL, Quesenberry CP.
    J Am Acad Dermatol; 2017 Apr; 76(4):632-638. PubMed ID: 28162854
    [Abstract] [Full Text] [Related]

  • 11. Fulfilling an unmet need in psoriasis : do biologicals hold the key to improved tolerability?
    Shear NH.
    Drug Saf; 2006 Apr; 29(1):49-66. PubMed ID: 16454534
    [Abstract] [Full Text] [Related]

  • 12. Carcinogenic risks of psoralen UV-A therapy and narrowband UV-B therapy in chronic plaque psoriasis: a systematic literature review.
    Archier E, Devaux S, Castela E, Gallini A, Aubin F, Le Maître M, Aractingi S, Bachelez H, Cribier B, Joly P, Jullien D, Misery L, Paul C, Ortonne JP, Richard MA.
    J Eur Acad Dermatol Venereol; 2012 May; 26 Suppl 3():22-31. PubMed ID: 22512677
    [Abstract] [Full Text] [Related]

  • 13. Comparative tolerability of systemic treatments for plaque-type psoriasis.
    McClure SL, Valentine J, Gordon KB.
    Drug Saf; 2002 May; 25(13):913-27. PubMed ID: 12381213
    [Abstract] [Full Text] [Related]

  • 14. Ultraviolet B Phototherapy for Psoriasis: Review of Practical Guidelines.
    Mehta D, Lim HW.
    Am J Clin Dermatol; 2016 Apr; 17(2):125-33. PubMed ID: 26872953
    [Abstract] [Full Text] [Related]

  • 15. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.
    Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS.
    JAMA Dermatol; 2015 Apr; 151(4):432-8. PubMed ID: 25517130
    [Abstract] [Full Text] [Related]

  • 16. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest.
    Reich K, Mrowietz U, Radtke MA, Thaci D, Rustenbach SJ, Spehr C, Augustin M.
    Arch Dermatol Res; 2015 Dec; 307(10):875-83. PubMed ID: 26358263
    [Abstract] [Full Text] [Related]

  • 17. Adverse events from systemic therapies for psoriasis are common in clinical practice.
    Pearce DJ, Higgins KB, Stealey KH, Balkrishnan R, Crane MM, Camacho F, Fleischer AB, Feldman SR.
    J Dermatolog Treat; 2006 Dec; 17(5):288-93. PubMed ID: 17092859
    [Abstract] [Full Text] [Related]

  • 18. The status of biologic therapies in the treatment of moderate to severe psoriasis.
    Menter A.
    Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
    [Abstract] [Full Text] [Related]

  • 19. Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?
    Langley RG.
    J Eur Acad Dermatol Venereol; 2012 Mar; 26 Suppl 2():21-9. PubMed ID: 22356632
    [Abstract] [Full Text] [Related]

  • 20. Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based Analysis.
    Wu JJ, Armstrong A, Singh R, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Arikan D, Fleischer A, Guérin A, Ganguli A.
    J Drugs Dermatol; 2018 Nov 01; 17(11):1211-1218. PubMed ID: 30500143
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.